Jounce Therapeutics, Inc. (JNCE)
$1.19
Rating:
Recommendation:
Buy
| Symbol | JNCE |
|---|---|
| Price | $1.19 |
| Beta | 0.643 |
| Volume Avg. | 1.60M |
| Market Cap | 61.516M |
| Shares () | - |
| 52 Week Range | 0.577-8.8 |
| 1y Target Est | - |
| DCF Unlevered | JNCE DCF -> | |
|---|---|---|
| DCF Levered | JNCE LDCF -> | |
| ROE | -58.21% | Strong Sell |
| ROA | -64.43% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 22.20% | Neutral |
| P/E | - | |
| P/B | 0.48 | Neutral |
Latest JNCE news
About
Download (Excel)Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.